Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2001 2
2003 3
2004 4
2005 5
2006 3
2007 7
2008 5
2009 2
2010 4
2011 3
2012 11
2013 11
2014 9
2015 11
2016 9
2017 8
2018 5
2019 14
2020 17
2021 19
2022 16
2023 11
2024 8

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

159 results

Results by year

Filters applied: . Clear all
Page 1
2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party.
Heuser M, Freeman SD, Ossenkoppele GJ, Buccisano F, Hourigan CS, Ngai LL, Tettero JM, Bachas C, Baer C, Béné MC, Bücklein V, Czyz A, Denys B, Dillon R, Feuring-Buske M, Guzman ML, Haferlach T, Han L, Herzig JK, Jorgensen JL, Kern W, Konopleva MY, Lacombe F, Libura M, Majchrzak A, Maurillo L, Ofran Y, Philippe J, Plesa A, Preudhomme C, Ravandi F, Roumier C, Subklewe M, Thol F, van de Loosdrecht AA, van der Reijden BA, Venditti A, Wierzbowska A, Valk PJM, Wood BL, Walter RB, Thiede C, Döhner K, Roboz GJ, Cloos J. Heuser M, et al. Among authors: ofran y. Blood. 2021 Dec 30;138(26):2753-2767. doi: 10.1182/blood.2021013626. Blood. 2021. PMID: 34724563 Free PMC article.
Acute myeloid leukaemia in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Heuser M, Ofran Y, Boissel N, Brunet Mauri S, Craddock C, Janssen J, Wierzbowska A, Buske C; ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Heuser M, et al. Among authors: ofran y. Ann Oncol. 2020 Jun;31(6):697-712. doi: 10.1016/j.annonc.2020.02.018. Epub 2020 Mar 17. Ann Oncol. 2020. PMID: 32171751 Free article. No abstract available.
Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia in First Remission.
Wei AH, Döhner H, Pocock C, Montesinos P, Afanasyev B, Dombret H, Ravandi F, Sayar H, Jang JH, Porkka K, Selleslag D, Sandhu I, Turgut M, Giai V, Ofran Y, Kizil Çakar M, Botelho de Sousa A, Rybka J, Frairia C, Borin L, Beltrami G, Čermák J, Ossenkoppele GJ, La Torre I, Skikne B, Kumar K, Dong Q, Beach CL, Roboz GJ; QUAZAR AML-001 Trial Investigators. Wei AH, et al. Among authors: ofran y. N Engl J Med. 2020 Dec 24;383(26):2526-2537. doi: 10.1056/NEJMoa2004444. N Engl J Med. 2020. PMID: 33369355 Clinical Trial.
Computational design of antibodies.
Fischman S, Ofran Y. Fischman S, et al. Among authors: ofran y. Curr Opin Struct Biol. 2018 Aug;51:156-162. doi: 10.1016/j.sbi.2018.04.007. Epub 2018 May 20. Curr Opin Struct Biol. 2018. PMID: 29791878 Review.
Gilteritinib with or without venetoclax for relapsed/refractory FLT3-mutated acute myeloid leukaemia.
Kugler E, Cohen I, Amitai I, Ram R, Frisch A, Nachmias B, Canaani J, Moshe Y, Krayem B, Aumann S, Henig I, Vainstein V, Shargian L, Ganzel C, Yeshurun M, Levi I, Raanani P, Akria L, Ofran Y, Shimony S, Wolach O. Kugler E, et al. Among authors: ofran y. Br J Haematol. 2024 Sep;205(3):932-941. doi: 10.1111/bjh.19548. Epub 2024 May 23. Br J Haematol. 2024. PMID: 38782575
Antibody specific epitope prediction-emergence of a new paradigm.
Sela-Culang I, Ofran Y, Peters B. Sela-Culang I, et al. Among authors: ofran y. Curr Opin Virol. 2015 Apr;11:98-102. doi: 10.1016/j.coviro.2015.03.012. Epub 2015 Mar 31. Curr Opin Virol. 2015. PMID: 25837466 Free PMC article. Review.
159 results